«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

期数:

2018年05期

页码:

536-541

栏目:

论著

出版日期:

2018-05-20

文章信息/Info

Title:

Correlation between serum macrophage migration inhibitory factor and microinflammation state and left ventricular hypertrophy in patients with hemodialysis

作者:

刘岩;  卢连元;  和玉芬

山东省泰安市中心医院肾病二科，山东泰安271000

Author(s):

LIU Yan;  LU Lian-yuan;  HE Yu-fen

Department of Nephrology second division, Taian City Central Hospital, Shandong 271000, China Corresponding author: LIU Yan, E-mial: liuyankv3000@163.com

关键词:

血液透析; 微炎症状态; 巨噬细胞移动抑制因子; 尿毒症心肌病; 心室肥厚

Keywords:

Hemodialysis;  Inflammation;  Macrophage migration inhibitory factor;  Uremic cardiomyopathy;  Ventricular hypertrophy

分类号:

R459.5；R542.5

DOI:

-

摘要:

目的探讨维持性血液透析患者血清巨噬细胞移动抑制因子（MIF） 与心肌肥厚的相关性。方法选取 2014 年10 月—2015 年8 月山东省泰安市中心医院肾病内科住院的51 例低通量血液透析患者为观察组，选取30 例 健康志愿者作为对照组。MIF 检测应用Bio-Plex 细胞因子检测法。左室质量指数应用超声心电图检测。根据超 声结果将终末期血液透析患者分为左心室肥厚患者和非左心室肥厚患者，采用logistic 回归分析确定相对危险度 （RR）。结果观察组患者血清MIF 水平明显高于对照组，差异有统计学意义（P<0.05）。伴有左心室肥厚的血 液透析患者血清MIF 水平明显高于非左室肥厚的血液透析患者（P＜0.05）。血清MIF 水平与左心室质量指数呈 正相关（Z=-4.108，P＜0.01）。结论血清MIF 促进了维持性血液透析患者尿毒症心肌病的发生与发展。

Abstract:

Objective To investigate the effects of serum macrophage migration inhibitory factor （MIF） on myocardial hypertrophy in hemodialysis patients. Methods A total of 51 cases of paitents with low flux hemaodialysis were recruited in the study group from Department of Renal Medicine, the central hospital of Taian during October 2014 to August 2015, and 30 healthy subjects were enrolled in control group. MIF was determined using the Bio-Plex cytokine assay. Left ventricular mass index （LVMI） was calculated by color Doppler ultrasound measurements. According to the results of cardiac Doppler ultrasound, hemaodialysis patients were divided into hypertrophy group and nonhypertrophy group. Relative risk was analyzed by logistic regressive analysis. Results The serum MIF level of study group was higher than that in the control group, and there was statistically significant （P< 0.05） . The serum levels of MIF in hypertrophy group were significantly higher than those in nonhypertrophy group （P<0.05） . There was a positive correlation between the serum MIF level and the left ventricular mass index （Z=-4.108, P＜0.01） . Conclusions Serum MIF can results in the occurrence and progress of uremic cardiomyopathy in patients with hemodialysis.

参考文献/References:

[1] 麻鹏磊,王祥,李冰,等.尿毒症心肌病的研究及临床治疗进展[J]. 中国老年学杂志,2016,36(9):2294-2297.
[2] Cafka M, Rroji M, Seferi S, et al. Inflammation, Left Ventricular Hypertrophy, and Mortality in End- stage Renal, Disease [J]. Iran J Kidney Dis, 2016,10(4):217-223.
[3] Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure [J]. Kidney Int, 2009,75(8):800-808.
[4] 宋国巍,王磊. 现有透析疗法对慢性肾衰竭尿毒症患者微炎症状 态的影响[J].中国实验诊断学,2015,19(7):1199-1200.
[5] Samet JM. Is there more to learn about the epidemiology of lung cancer [J]. Eur J Epidemiol, 2016,31(12):1159- 1160.
[6] Tripathi G, Borkar M, Akhter A, et al. Association of proinflammatory cytokines with end stage renal disease[J]. Cytokine, 2010,50(3):278-283.
[7] Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline [J]. Ann Intern Med, 2013,158(11):825-830.
[8] Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention [J]. Hypertension, 2003,42(5):1050-1065.
[9] 符会妮,董平栓,丁旭萌.二维斑点追踪成像技术评价高血压患者 左室收缩功能的价值[J]. 心血管康复医学杂志,2016,25(3)324- 327.
[10] Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD [J]. Am J Kidney Dis, 2005,46(2):320-327.
[11] 朱祥胜,李国杰.尿毒症心肌病研究进展[J].国外医学:老年医学分 册,2009,30(1):8-11.
[12] Bozza FA, Gomes RN, Japiassú AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis [J]. Shock, 2004,22(4):309-313.
[13] Tsirpanlis G, Chatzipanagiotou S, Nicolaou C. Microinflammation versus inflammation in chronic renal failure patients [J]. Kidney Int, 2004,66(5):2093-2094.
[14] Kindt N, Journe F, Laurent G, et al. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets [J]. Oncol Lett, 2016,12(4):2247-2253.
[15] Javeed A, Zhao Y, Zhao Y. Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection [J]. Inflamm Res, 2008,57(2):45-50.
[16] 申万琴. 血必净注射液对慢性肾衰患者微炎症状态影响分析[J]. 中国现代药物应用,2016,10(2):144-145.
[17] 郭林,贺小霞. 血液透析、腹膜透析两种透析方式对慢性肾衰尿 毒症患者微炎症状态的影响[J].临床医药文献电子杂志,2015,2 (21):4327-4328.
[18] Tomé FS, Senger M, Garcez C, et al. Dialysis water treated by reverse osmosis decreases the levels of C- reactive protein in uremic patients [J]. Braz J Med Biol Res, 2005,38(5):789-794.
[19] Boenisch O, Eh.mke KD, Heddergott A, et al. C-reactiveprotein and cytokine plasma levels in hemodialysis patients [J]. J Nephrol, 2002,15(5):547-551.
[20] Nardi E, Palermo A, Mulè G, et al. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease [J]. J Hypertens, 2009,27(3):633- 641.
[21] Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity [J]. Nat Rev Immunol, 2003,3(10):791-800.
[22] Matsui Y, Okamoto H, Jia N, et al. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis [J]. J Mol Cell Cardiol, 2004,37 (2):557-566.
[23] Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74 [J]. J ExP Med, 2003, 197(11):1467-1476.
[24] Shioji K, Kishimoto C, Sasayama S. Fc receptor- mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells [J]. Circ Res, 2001,89(6):540- 546.

备注/Memo

备注/Memo:

作者简介：刘岩，博士，主治医师，研究方向：肾脏病的 诊治 通信作者：刘岩，Email：liuyankv3000@163.com

常用功能

更新日期/Last Update: 2018-05-28